2025-05-29 - Analysis Report
Okay, here's a comprehensive analysis of Albemarle Corp (ALB) based on the provided data.

**Report on Albemarle Corp (ALB)**

**1. Relative Performance vs. S&P 500 (VOO)**

*   **Ticker:** ALB
*   **Company Overview:** Albemarle Corp is a specialty chemicals company with leading positions in lithium, bromine specialties, and catalysts.

**Key Performance Metrics:**

*   **ALB Cumulative Return:** 1.88%
*   **VOO Cumulative Return:** 82.09%
*   **Absolute Divergence (ALB - VOO):** -80.21%
*   **Divergence Range:** Max: 308.0, Min: -81.5
*   **Relative Divergence:** 0.3 (Indicates that the current divergence is near the lowest end of its historical range)

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta | Cap(B) |
|------------|---------|---------|---------|------|--------|
| 2015-2017  | 99.0%   | 7.7%    | 70.0%   | 0.0  | 13.7   |
| 2016-2018  | 13.0%   | 58.1%   | -5.0%   | 0.0  | 8.4    |
| 2017-2019  | -45.0%  | 58.1%   | -74.0%  | -0.0 | 8.1    |
| 2018-2020  | 101.0%  | 62.9%   | 75.0%   | 0.7  | 16.6   |
| 2019-2021  | 268.0%  | 62.9%   | 214.0%  | 0.8  | 26.5   |
| 2020-2022  | 239.0%  | 75.8%   | 233.0%  | 1.1  | 24.8   |
| 2021-2023  | -53.0%  | 77.6%   | -69.0%  | 0.6  | 16.6   |
| 2022-2024  | -204.0% | 77.6%   | -221.0% | 0.8  | 10.1   |
| 2023-2025  | -346.0% | 77.6%   | -376.0% | 3.4  | 6.8    |

**Analysis:**

*   ALB has significantly underperformed the S&P 500, with a substantial negative divergence in cumulative returns.
*   The relative divergence of 0.3 indicates that this underperformance is near the worst end of its historical range.
*   The Alpha/Beta analysis reveals a highly variable performance history.  During periods of strong market growth (e.g., 2019-2021), ALB delivered substantial alpha. However, recent years (2021-2025) show significant underperformance and negative alpha.  The Beta values generally indicate a moderate to high correlation with the market, particularly in recent periods. Noticeable increased of Beta in the latest period (2023-2025) indicate that it is very sensitive to market movements.

**2. Recent Stock Price Movements**

*   **Current Price:** $58.05
*   **Previous Close:** $58.79
*   **Price Change:** -$1.26
*   **5-day Moving Average:** $57.77
*   **20-day Moving Average:** $58.87
*   **60-day Moving Average:** $64.13

**Analysis:**

*   The stock price has experienced a recent decline.
*   The current price is below the 20-day and 60-day moving averages, which might indicate a short-term downtrend.
*   The price closing lower than the previous day signals potential further downward momentum.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 56.58
*   **PPO:** 0.25
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.38)
*   **20-day Relative Divergence Change:** 0.1 (Positive - short-term increase)
*   **Expected Return:** 13191.2% (Long-term, S&P 500 outperformance)

**Analysis:**

*   The MRI suggests a low-risk environment, which seems contradictory given the company's recent performance. This could be a broader market assessment not specific to ALB.
*   The RSI of 56.58 is approaching overbought levels, suggesting a possible price correction in the short term.
*   PPO is slightly positive, suggesting very marginal bullishness, it should be considered almost neutral.
*   The hybrid signal recommends buying a small portion of shares, but with caution due to the MRI.
*   The recent positive change in relative divergence suggests a short-term upward trend.
*   The extremely high expected return should be viewed with extreme skepticism.  Such high returns are highly unlikely and potentially based on flawed modeling.
*   The price change of -1.26 from the previous close, while not extreme, indicates continuing downward pressure, reflecting recent negative news.

**4. Recent News & Significant Events**

*   **[2025-05-28]:** Major business developments, regulatory changes, or market events.
*   **[2025-05-25]:** Analyst discussions on performance and outlook.
*   **[2025-05-26]:** Notable stock volatility due to recent news, earnings reports, or executive actions.
*   **[2025-05-27]:** Experts highlight risks and opportunities.

**Analysis:**

*   Recent news suggests significant activity and volatility surrounding Albemarle. Investors should closely monitor news and company announcements. The mixed signals of risks and opportunities need further investigation.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue     |
|------------|-------|-------------|
| 2025-04-30 | 0    | 1.08 B$    |
| 2024-11-06 | -9.45 | 1.35 B$    |
| 2024-07-31 | -1.96 | 1.43 B$    |
| 2024-05-01 | -0.08 | 1.36 B$    |
| 2025-04-30 | -0.08 | 1.36 B$    |

**Analysis:**

*   The EPS has been volatile and generally negative, with significant losses in recent quarters.  The most recent quarter shows an EPS of 0.
*   Revenue has generally declined over the past year. This suggests potential challenges in the company's core business.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-03-31   | $1.08B      | 14.51%         |
| 2024-12-31   | $1.23B      | 11.22%         |
| 2024-09-30   | $1.35B      | -7.68%        |
| 2024-06-30   | $1.43B      | -0.74%        |
| 2024-03-31   | $1.36B      | 2.86%          |

**Capital and Profitability:**

| Quarter      | Equity      | ROE     |
|--------------|-------------|---------|
| 2025-03-31   | $10.03B     | 0.41%   |
| 2024-12-31   | $9.96B      | 0.76%   |
| 2024-09-30   | $10.24B     | -10.44% |
| 2024-06-30   | $11.22B     | -1.68%  |
| 2024-03-31   | $11.53B     | 0.02%   |

**Analysis:**

*   Revenue has generally been decreasing quarter-over-quarter.
*   Profit margins have fluctuated and even turned negative in recent quarters, indicating potential cost pressures or pricing issues.
*   Equity has generally decreased, while ROE has been volatile and largely negative, reflecting poor profitability.

**7. Overall Analysis & Conclusion**

Albemarle Corp (ALB) is facing significant challenges. Its stock has underperformed the S&P 500 substantially, and recent financial data reveals declining revenue, volatile and often negative earnings, and profitability issues. Recent news indicates ongoing volatility and uncertainty. While the MRI suggests low overall market risk, ALB's specific financial indicators paint a concerning picture. The extremely high expected return is unlikely to be realized.

**Recommendation:**

Based on the provided data, a **cautious approach** is warranted. Investors should closely monitor Albemarle's upcoming earnings reports and news releases for signs of improvement. Given the negative trends in earnings, revenue, and profitability, along with the high volatility, it may be prudent to avoid or reduce exposure to ALB until there are clear indications of a turnaround. A deeper dive into the reasons for the revenue decline, cost pressures, and strategic initiatives to address these challenges is essential for making an informed investment decision.
